The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure
Abstract
Background—The vasoconstrictor peptide endothelin-1 (ET-1) is important for increased vascular tone in patients with chronic heart failure, but the effects of endothelin-receptor blockade in addition to conventional triple therapy are unknown. Methods and Results—Thirty-six men (mean age±SD, 55±8 years) with symptomatic heart failure (NYHA class III; left ventricular ejection fraction, 22.4±4.5%) despite treatment with diuretics, digoxin, and ACE inhibitors received, in a double-blind and randomized fashion, either additional oral bosentan (1.0 g BID; n=24) or placebo (n=12) over 2 weeks. Hemodynamic and hormonal (plasma ET-1, norepinephrine, renin activity, and angiotensin II) measurements were obtained before and repeatedly for 24 hours after administration of bosentan on days 1 and 14. Bosentan was discontinued in 1 patient with symptomatic hypotension, and 2 patients (bosentan group) declined hemodynamic investigations on day 14. Compared with placebo, bosentan on day 1 significantly decreased mean arterial pressure (difference from baseline over 12 hours [95% CIs], −13.9% [−16.0% to −11.7%]), pulmonary artery mean (−12.9% [−17.4% to −8.3%]) and capillary wedge (−14.5% [−20.5% to −8.5%]) pressures, and right atrial pressure (−20.2% [−29.4% to −11.0%]). Cardiac output increased (15.1% [10.7% to 19.7%]), but heart rate was unchanged. Both systemic (−24.2% [−28.1% to −20.3%]) and pulmonary (−19.9% [−28.4% to −11.4%]) vascular resistance were reduced. After 2 weeks, cardiac output had further increased (by 15.2% [10.8% to 19.6%]) and systemic (−9.3% [−12.3% to −6.4%]) and pulmonary (−9.7% [−16.3% to −3.1%]) vascular resistances further decreased compared with day 1. Heart rate remained unchanged. Plasma ET-1 levels increased after bosentan, but baseline levels of the other hormones were unchanged. Conclusions—Additional short-term oral endothelin-receptor antagonist therapy improved systemic and pulmonary hemodynamics in heart failure patients who were symptomatic with standard triple-drug therapy. Further investigations are warranted to characterize the effects of long-term endothelin-receptor antagonist therapy on symptoms, morbidity, and mortality in such patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel potent vasoconstrictor peptide produced by vascular endothelial cells
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., & Masaki, T. (1988) · Nature · doi:10.1038/332411a0 · Cited by 10,729
Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide.
Boulanger, C., & Lüscher, T. F. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114477 · Cited by 1,045
Clozel, M., Breu, V, Gray, G. A., Kalina, B., Löffler, B. M., Burri, K., Cassal, J. M., Hirth, G., Müller, M., & Neidhart, W. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22357-6 · Cited by 661
Cody, R. J., Haas, G. J., Binkley, P. F., Capers, Q., & Kelley, R. (1992) · Circulation · doi:10.1161/01.cir.85.2.504 · Cited by 647
Inhibition of myocardial endothelin pathway improves long-term survival in heart failure
Sakai, S., Miyauchi, T., Kobayashi, M., Yamaguchi, I., Goto, K., & Sugishita, Y. (1996) · Nature · doi:10.1038/384353a0 · Cited by 622
Endothelin in human congestive heart failure.
Wei, C. M., Lerman, A., Rodeheffer, R. J., McGregor, C. G., Brandt, R. R., Wright, S., Heublein, D. M., Kao, P. C., Edwards, W. D., & Burnett, J. C. (1994) · Circulation · doi:10.1161/01.cir.89.4.1580 · Cited by 586
Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
Kiowski, W., Kim, J., Oechslin, E., Sütsch, G., Hunziker, P., Müller, P., Bertel, O., Schmitt, R., & Jones, R. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91504-4 · Cited by 571
Self-citationKrum, H., Viskoper, R. J., Lacourciere, Y., Budde, M., & Charlon, V. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803193381202 · Cited by 570
Mefford, I. N. (1981) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(81)90056-x · Cited by 520
Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels.
Seo, B., Oemar, B. S., Siebenmann, R., von Segesser, L., & Lüscher, T. F. (1994) · Circulation · doi:10.1161/01.cir.89.3.1203 · Cited by 517
Cited by
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., Rosenson, R. S., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.01.004 · Cited by 2,360
Cardiac Fibrosis: The Fibroblast Awakens
Travers, J. G., Kamal, F. A., Robbins, J., Yutzey, K. E., & Blaxall, B. C. (2016) · Circulation Research · doi:10.1161/circresaha.115.306565 · Cited by 1,596
Writing Committee Members, McLaughlin, V. V., Archer, S. L., Badesch, D. B., Barst, R. J., Farber, H. W., Lindner, J. R., Mathier, M. A., McGoon, M. D., Park, M. H., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192230 · Cited by 1,093
Pulmonary Arterial Hypertension
McLaughlin, V. V., & McGoon, M. D. (2006) · Circulation · doi:10.1161/circulationaha.104.503540 · Cited by 664
Lüscher, T. F., & Barton, M. (2000) · Circulation · doi:10.1161/01.cir.102.19.2434 · Cited by 596
Metadata
- Authors
- Sütsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., & Bertel, O.
- Venue
- Circulation
- Published
- 1998-11-24
- Volume
- 98
- Issue
- 21
- Pages
- 2262-2268
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2104825830
- Cited by
- 287
- References
- 21
- FWCI
- 24.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure. https://app.cochat.ai/papers/10.1161/01.cir.98.21.2262
- The paper
- Sütsch, G., Kiowski, W., Yan, X.-W., Hunziker, P., Christen, S., Strobel, W., Kim, J.-H., Rickenbacher, P., & Bertel, O. (1998). Short-Term Oral Endothelin-Receptor Antagonist Therapy in Conventionally Treated Patients With Symptomatic Severe Chronic Heart Failure. Circulation. https://doi.org/10.1161/01.cir.98.21.2262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.